REG - ValiRx PLC - Notice of GM <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

27/06/2016 07:05

RNS Number : 2725C
ValiRx PLC
27 June 2016
ValiRx Plc
("ValiRx" or the "Company")
Shareholder Circular and Notice of General Meeting
London, UK. 27th June 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that it has today published and posted to shareholders a circular in relation to a forthcoming General Meeting, due to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 11:30 a.m. on 12th July 2016.
The directors will propose at the General Meeting a shareholder resolution seeking consent for the dis-application of pre-emptive rights.
A copy of the Circular is available on the Company's website.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Richard Nash



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)


This information is provided by RNS
The company news service from the London Stock Exchange
  END
NOGAKQDKOBKDQAB